Autonomic dysfunction as manifestation of ICANS: A case report

Dina Rochate,Antonio Manuel González-García,Carmen Santos Marcos,Estefanía Pérez-López,Ana-África Martín-López,Mónica Alaña,Lourdes Martín Martín,Miriam López Parra,Fermín Sánchez Guijo,Lucía López Corral

DOI: https://doi.org/10.1097/md.0000000000038659

IF: 1.6

2024-11-08

Medicine

Abstract:Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is a successful treatment for B-cell malignancies, though its association with multiple adverse effects, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), is well described. [ 1 ] Due to its potentially life-threatening nature, ICANS is considered a severe complication of CAR-T therapy, which occurs in 20% to 60% of patients, of whom 12% to 30% have severe (≥grade 3) symptoms. [ 2 ] Its pathophysiology remains to be elucidated but it is thought to be secondary to inflammatory cytokines action related to disruption of blood-brain barrier (BBB) due to either its passive diffusion into the brain or the presence of activated T-cells in the central nervous system (CNS). [ 3 , 4 ] Symptoms of ICANS are variable and can initially be vague. Typically, ICANS manifests as frontal encephalopathy, however, its clinical spectrum can highly vary in type and severity, ranging from a mild headache to severe impairment including delirium, seizures or cerebral edema. [ 5 ] ICANS is a clinical diagnosis and brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) evaluation are necessary to rule out alternative diagnosis. Management of ICANS is based on the severity of the score and the concurrence of CRS. [ 4 ] The prognosis is good and the majority of patients fully recover without any long-term sequelae. Cardiovascular side effects related to CRS were recently described, including cardiovascular mortality, new onset heart failure, heart failure decompensation, and new arrhythmias. Although arterial hypotension and orthostatic hypotension were studied as effects of CAR-T therapy, autonomic disorders have been described but not clearly characterized as ICANS manifestations. [ 6 ] Postural orthostatic tachycardia syndrome (POTS), is a heterogeneous multifactorial disorder characterized by orthostatic tachycardia with associated symptoms and relief by recumbent posture and accompanied by evidence of autonomic dysfunction. [ 7 ] Potential causes of orthostatic hypotension have been suggested, such as older age, history of hypertension and use of medications (anti-hypertensives, diuretics, antidepressants and neuroleptics). Orthostatic hypotension may be due to autonomic nervous system dysfunction, with different clinical manifestations depending on whether sympathetic or parasympathetic involvement predominates. [ 8 ] In neuropathies, there may be autonomic involvement, with different cardiovascular symptoms. There is also a relationship between dysautonomia and various inflammatory processes. There is a growing body of evidence that the etiology of POTS (one of the most common autonomic disorder, with a wide range of clinical manifestations, such as postural tachycardia, orthostatic intolerance, presyncope, dyspnea, chest pain, exercise intolerance and noncardiac manifestations such as dizziness, headaches, muscles weakness, fatigue and sleep disturbances), [ 9 ] may have immune-mediated pathogenesis as it was recently portrayed with association with COVID-19. [ 7 , 10 ] Also, a case of dysautonomia as a manifestation of neurotoxicity after CAR-T therapy has been described in literature. [ 3 ] Considering our limited understanding of autonomic dysfunction after CAR-T therapy, we report a case of a patient with non-Hodgkin-B-cell lymphoma treated with anti-CD19 CAR-T therapy who developed orthostatic hypotension secondary as manifestation of ICANS.

medicine, general & internal